RCUS vs. APLS, RNA, CRNX, IMVT, ACLX, MRUS, XENE, IDYA, ADMA, and RYTM
Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Apellis Pharmaceuticals (APLS), Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Arcellx (ACLX), Merus (MRUS), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), ADMA Biologics (ADMA), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.
Arcus Biosciences (NYSE:RCUS) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.
Apellis Pharmaceuticals has a net margin of -79.67% compared to Arcus Biosciences' net margin of -97.47%. Arcus Biosciences' return on equity of -40.98% beat Apellis Pharmaceuticals' return on equity.
Apellis Pharmaceuticals received 135 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 67.44% of users gave Apellis Pharmaceuticals an outperform vote while only 65.03% of users gave Arcus Biosciences an outperform vote.
Arcus Biosciences has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Arcus Biosciences currently has a consensus target price of $38.11, suggesting a potential upside of 141.06%. Apellis Pharmaceuticals has a consensus target price of $74.75, suggesting a potential upside of 88.05%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Apellis Pharmaceuticals.
In the previous week, Apellis Pharmaceuticals had 16 more articles in the media than Arcus Biosciences. MarketBeat recorded 20 mentions for Apellis Pharmaceuticals and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.50 beat Apellis Pharmaceuticals' score of 0.48 indicating that Arcus Biosciences is being referred to more favorably in the media.
Arcus Biosciences has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Arcus Biosciences beats Apellis Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Arcus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcus Biosciences Competitors List
Related Companies and Tools
